Royalty Pharma Price To Sales Ratio Over Time
| RPRX Stock | USD 26.00 0.36 1.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Royalty Pharma Performance and Royalty Pharma Correlation. Royalty |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.587 | Dividend Share 0.83 | Earnings Share 2.54 | Revenue Per Share 5.055 | Quarterly Revenue Growth 0.053 |
The market value of Royalty Pharma Plc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty Pharma's value that differs from its market value or its book value, called intrinsic value, which is Royalty Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty Pharma's market value can be influenced by many factors that don't directly affect Royalty Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Royalty Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Sales Ratio Analysis
Compare Royalty Pharma Plc and related stocks such as Prime Medicine, Common, Reneo Pharmaceuticals, and Ginkgo Bioworks Holdings Price To Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 7.8 K | 36.0071 | 5.9401 | 13.0682 | 12.41 |
| OCEA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ADPT | 111 | 111 | 111 | 111 | 111 | 111 | 111 | 111 | 76.3339 | 24.3259 | 78.8643 | 25.5168 | 5.8757 | 4.1549 | 3.95 |
| IKNA | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 1.2 K | 83.4174 | 125 | 14.5595 | 6.1635 | 8.9758 | 8.53 |
| ASND | 9.8914 | 9.8914 | 9.8914 | 7.2458 | 18.8449 | 49.2168 | 111 | 729 | 212 | 431 | 993 | 833 | 125 | 24.0469 | 22.84 |
| APLS | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 59.9646 | 72.7527 | 17.9128 | 33.56 |
| BGNE | 134 | 134 | 134 | 134 | 114 | 101 | 1.1 K | 18.6695 | 39.2311 | 23.2468 | 69.8286 | 21.371 | 16.02 | 7.6572 | 7.27 |
| AKRO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| BPMC | 42.1339 | 42.1339 | 42.1339 | 42.1339 | 42.1339 | 42.1339 | 27.7669 | 133 | 53.1181 | 57.6074 | 7.7053 | 34.806 | 12.8062 | 22.399 | 21.28 |
| IOVA | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.6 K | 1.4 K | 1.3 K |
| CVAC | 666 | 666 | 666 | 666 | 666 | 666 | 666 | 666 | 666 | 535 | 179 | 54.4947 | 15.7929 | 15.9736 | 15.17 |
| MDGL | 152 | 29.0624 | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.3 K | 3.4 K |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Royalty Pharma Plc and related stocks such as Prime Medicine, Common, Reneo Pharmaceuticals, and Ginkgo Bioworks Holdings Price To Sales Ratio description
Price to Sales Ratio is figured by comparing Royalty Pharma Plc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Royalty Pharma sales, a figure that is much harder to manipulate than other Royalty Pharma Plc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.My Equities
My Current Equities and Potential Positions
| Royalty Pharma Plc | RPRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 26.0
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.